On ECHEMI
Home > Drugs > Chongqing Lummy Pharmaceutical Co., Ltd.
Chongqing Lummy Pharmaceutical Co., Ltd.
  • Founded in:

    1999-09-06
  • Country:

    China China
  • Address:

    No. 99, Yuma Road, Nan'an District, Chongqing
  • Tax NO.:

    915000006219193432
  • Registered Funds:

    1,055,911,205 yuan
  • Website:

  • Email:

Related Drugs
Tranexamic Acid Injection
The main ingredient is tranexamic acid.
Name Description Content CAS NO. Registered Holders
Tranexamic Acid

Competitively inhibit the adsorption of plasminogen on fibrin, prevent its activation, protect fibrin from being degraded and dissolved by plasmin, and achieve hemostatic effect; directly inhibit plasmin activity, reduce the effect of plasmin activating complement, and prevent the occurrence of hereditary angioedema.

More

Competitively inhibit the adsorption of plasminogen on fibrin, prevent its activation, protect fibrin from being degraded and dissolved by plasmin, and achieve hemostatic effect; directly inhibit plasmin activity, reduce the effect of plasmin activating complement, and prevent the occurrence of hereditary angioedema.

1197-18-8 30
Tranexamic Acid Injection
The chemical name of this product is: -4-aminomethylcyclohexanecarboxylic acid.
Name Description Content CAS NO. Registered Holders
Tranexamic acid

Competitively inhibit the adsorption of plasminogen on fibrin, prevent its activation, protect fibrin from being degraded and dissolved by plasmin, and achieve hemostatic effect; at the same time, directly inhibit the activity of plasmin, reduce the effect of plasmin in activating complement, and prevent the occurrence of hereditary angioedema.

More

Competitively inhibit the adsorption of plasminogen on fibrin, prevent its activation, protect fibrin from being degraded and dissolved by plasmin, and achieve hemostatic effect; at the same time, directly inhibit the activity of plasmin, reduce the effect of plasmin in activating complement, and prevent the occurrence of hereditary angioedema.

701-54-2 0
Sodium Ferulate for Injection
Sodium ferulate.
Name Description Content CAS NO. Registered Holders
Sodium ferulic

This product is a non-peptide endothelin receptor antagonist, which can antagonize endothelin-induced vasoconstriction, blood pressure increase and vascular smooth muscle cell proliferation, reduce vascular endothelial damage; increase NO synthesis, relax vascular smooth muscle; inhibit platelet aggregation, anti-coagulation, and improve blood rheology characteristics. This product can also inhibit cholesterol synthesis, lower blood lipids, scavenge free radicals, prevent lipid peroxidation damage; affect complement, enhance immune function, and have certain analgesic and antispasmodic effects.

More

This product is a non-peptide endothelin receptor antagonist, which can antagonize endothelin-induced vasoconstriction, blood pressure increase and vascular smooth muscle cell proliferation, reduce vascular endothelial damage; increase NO synthesis, relax vascular smooth muscle; inhibit platelet aggregation, anti-coagulation, and improve blood rheology characteristics. This product can also inhibit cholesterol synthesis, lower blood lipids, scavenge free radicals, prevent lipid peroxidation damage; affect complement, enhance immune function, and have certain analgesic and antispasmodic effects.

24276-84-4 8
Naloxone Hydrochloride for Injection
Main ingredients: Naloxone hydrochloride, auxiliary materials are mannitol, sodium dihydrogen phosphate, disodium hydrogen phosphate. Chemical name: 17-allyl-4,5a-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride dihydrate. Chemical structure: Molecular formula: C19H21NO4·HCl·2H2O Molecular weight: 399.87
Name Description Content CAS NO. Registered Holders
Naloxone hydrochloride

This product is an opioid receptor antagonist, which has almost no pharmacological activity itself, but can competitively antagonize various opioid receptors and has a strong affinity for m receptors. It can completely or partially correct the central inhibitory effects of opioid substances, such as respiratory depression, sedation and hypotension; it has a wake-up effect on animals with acute ethanol poisoning; it is a pure opioid receptor antagonist and does not cause respiratory depression, psychotomimetic reactions or miotic reactions; there is no drug resistance, nor physiological or mental dependence.

More

This product is an opioid receptor antagonist, which has almost no pharmacological activity itself, but can competitively antagonize various opioid receptors and has a strong affinity for m receptors. It can completely or partially correct the central inhibitory effects of opioid substances, such as respiratory depression, sedation and hypotension; it has a wake-up effect on animals with acute ethanol poisoning; it is a pure opioid receptor antagonist and does not cause respiratory depression, psychotomimetic reactions or miotic reactions; there is no drug resistance, nor physiological or mental dependence.

357-08-4 32
Naloxone Hydrochloride for Injection
Main ingredients: Naloxone hydrochloride, auxiliary materials are mannitol, sodium dihydrogen phosphate, disodium hydrogen phosphate. Chemical name: 17-allyl-4,5a-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride dihydrate. Chemical structure: Molecular formula: C19H21NO4·HCl·2H2O Molecular weight: 399.87
Name Description Content CAS NO. Registered Holders
Naloxone hydrochloride

This product is an opioid receptor antagonist, which has almost no pharmacological activity itself, but can competitively antagonize various opioid receptors and has a strong affinity for m receptors. It can completely or partially correct the central inhibitory effects of opioid substances, such as respiratory depression, sedation and hypotension; it has a wake-up effect on animals with acute ethanol poisoning; it is a pure opioid receptor antagonist and does not cause respiratory depression, psychotomimetic reactions or miotic reactions; there is no drug resistance, nor physiological or mental dependence.

More

This product is an opioid receptor antagonist, which has almost no pharmacological activity itself, but can competitively antagonize various opioid receptors and has a strong affinity for m receptors. It can completely or partially correct the central inhibitory effects of opioid substances, such as respiratory depression, sedation and hypotension; it has a wake-up effect on animals with acute ethanol poisoning; it is a pure opioid receptor antagonist and does not cause respiratory depression, psychotomimetic reactions or miotic reactions; there is no drug resistance, nor physiological or mental dependence.

357-08-4 32
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.